IInstylla develops medical devices for interventional radiology, focusing on liquid embolic agents. Its flagship Embrace HES uses two low-viscosity liquid precursors that, when injected, form a PEG hydrogel to permanently block blood flow, enabling embolization of hypervascular tumors and control of arterial bleeding; the system is solvent-free, deeply penetrates the tumor bed, and provides imaging-friendly follow-up. The company differentiates itself with a solvent-free, in situ forming hydrogel that creates durable occlusion and is backed by clinical data, including FDA PMA approval in 2025, and it is also developing Tembo, a bioresorbable embolic system. Instylla aims to bring advanced embolization solutions to interventional radiologists for oncology and hemorrhage control and to broaden commercialization of next-generation embolic technologies.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$63.5M
Headquarters
Bedford, MA
Founded
2017
See people who can refer or advise you
Total Funding
$63.5M
Above
Industry Average
Funded Over
3 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$63.5M
Headquarters
Bedford, MA
Founded
2017
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs